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Abstract
Brevibacterium spp. were considered apathogenic until a few 
reports of infections in immunocompromised patients were 
published. Herein, we present a case of a catheter-related 
septicemia with Brevibacterium casei in an immunocom-
petent patient receiving continuous iloprost infusion for 
pulmonary arterial hypertension and review the clinical 
presentation of this mainly emerging opportunistic pathogen.
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Introduction
Patients with indwelling foreign material bear considerable 
risk of acquiring bloodstream infections. Among a wide 
range of causative agents, Brevibacterium spp. are rarely 
found and were considered apathogenic until a few reports 
of clinically relevant infections with Brevibacterium spp. 
were reported mainly in immunocompromised patients 
[1]. Herein, we report a case of a central venous catheter 
(CVC) related blood stream infection with Brevibacterium 
casei in an immunocompetent patient and review the lit-
erature with emphasis on the clinical presentation of this 
emerging, mainly opportunistic pathogen.
Case Report
A 62-year-old violinist with severe pulmonary hypertension who 
was being treated with continuous intravenous iloprost via a non-
tunneled central venous catheter (CVC) presented with flu-like 
symptoms, productive cough and chills at our outpatient clinic. 
She was afebrile and routine blood analyses including C-reactive 
protein (CRP) were normal. Pulmonary infection was suspected 
and antibiotic therapy with moxifloxacin 400 mg twice daily was 
prescribed empirically for 5 days. But the patient’s general con-
dition failed to recover, although remaining afebrile. Slightly el-
evated neutrophils (8.2 × 103/ml) and CRP (8 mg/dl) were found 
as the only pathologic blood value and chest X-ray was without 
infiltrates. When she developed fever and chills several weeks 
after her first symptoms, the patient was hospitalized. Her body 
temperature was 38.4 °C (101.12 °F), heart rate 78 beats/min, 
blood pressure 159/60 mmHg, respiratory rate 24 breaths/min and 
the arterial oxygen saturation 85% while breathing ambient air. 
The lungs were clear on auscultation, a middle-loud systolic heart 
murmur was heard as previous. There was no erythema, pus or 
tenderness at the site of the CVC insertion. Blood for culture was 
obtained from two separate peripheral venipuncture sites. CRP 
had increased to 38 mg/dl; neutrophil count had normalized. Anti-
biotic therapy with moxifloxacin 400 mg twice daily was restarted 
empirically. Body temperature and CRP rapidly normalized.
Growth of Brevibacterium sp. was reported in both of the 
aerobic blood cultures. Antibiotic therapy was changed to intra-
venous vancomycin (1 g twice daily) and the CVC was changed. 
The same Brevibacterium sp. was cultured on the CVC that was 
removed, and the bacteria were further specified as Brevibacte-
rium casei. CVC-associated septicemia with B. casei was diag-
nosed. After 10 days of intravenous vancomycin, antibiotic therapy 
was switched to oral moxifloxacin 400 mg twice daily for another 
20 days according to microbiological sensitivity testing. During
this time, the patient recovered consistently. None of the 
following monthly surveillance blood cultures revealed B. casei
and up to 6 months later, the patient remained without further 
infectious complications.
Microbiology
The patient’s isolates of both the peripheral blood samples 
and CVC tip showed gram-positive short coryneform rods 
forming whitish gray colonies with a distinctive cheese-
like smell typical of Brevibacterium sp. Their identity 
was confirmed by conventional tests, i.e., production of 
methanethiol and hydrolysis of casein and tyrosine [2]. The 
isolate was identified as B. casei by use of carbohydrate 
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assimilation tests as previously described [2].  were 
0.75 mg/ml and 0.19 mg/l, respectively. Interpretative 
breakpoints are not available for coryneform bacteria, 
but our results of decreased susceptibilities to beta-
lactams are in line with the data of Funke et al. [3]. We 
assume from the clinical improvement of our patient that 
the isolate was susceptible to vancomycin and 
moxifloxacin.
Table 1
Clinical pictures of infections with Brevibacterium species.
Reference Type of 
Infection
Brevibacte-
rium species
Main 
underlying 
disease
Clinical 
symptoms
Indwelling 
foreign 
material
Symptom 
onset to 
treatment
Time to 
recurrence 
(days)
Treatment 
regimen(s)
McCaughey 
[13]
Septicemia Epidermidis Zollinger–Elli-
son Syndrome 
Weight loss, post-
prandial vomit-
ing, fever, slight 
erythema around 
CVCa
CVCa > 15 days No Erythromycin
Lina [14] Septicemia Not 
specified
Lymphoblastic 
lymphoma
Fever, diplopia, 
retroocular pain
CVCa > 23 days 28 Teicoplanin and 
amikacin 20 days, 
Teicoplanin 
21 days
Reinert [10] Septicemia Casei Testicular 
Chorion-
carcinoma
High fever, pancy-
topenia
CVCa Few days 13 Piperacillin and 
teicoplanin 
10 days, piperacillin 
and tobramycin 
10 days
Kaukoranta-
Tolvanen 
[12]
Septicemia Casei Non-Hodgkin’s    
Lymphoma
Initially high, 
recurrent fever, 
tachycardia, CRPb 
up to 42 mg/dl, 
pancytopenia
CVCa > 18 days 16 Not mentioned
Castagnola  
[1]
Septicemia Casei Neuro-blastoma Fever, neutrophil 
count above 
1,000/cm3
CVCa Not 
mentioned
No Not mentioned
Antoniou 
[18]
Peritonitis Iodinum CAPDc Fever, abdominal 
pain and tender-
ness, urticaria, 
pruritus, CRPb 
17.2 mg/dl
CAPDc -
Catheter
Rapid 
onset
No Intraperitoneal 
cefuroxime 
375 mg/exchange 
2 days, than cipro-
floxacin 50 mg/
exchange 6 days
Wauters 
[17]
Peritonitis Otitidis CAPDc due to 
nephro-sclerosis
Moderate abdomi-
nal pain, subfebril 
body temperature, 
effluent with 160 
white blood cells/
mm3 (46% PMNd)
CAPDc -
Catheter
Several 
days
No Intraperito-
neal cefazolin                 
and gentamicin
Brazzola 
[11]
Septicemia Casei AIDSe Persisting fever, 
dehydration
Port-à-
Cath
> 10 days No Ciprofloxacin 
14 days
Ogunc [15] Septicemia Not 
specified
Chronic 
lymphatic 
leucemia
High fever, slight 
leucocytosis 
(with 85% 
lymphocytes)
Not 
mentioned
Not 
reported
No Not mentioned
Janda [4] Septicemia Casei AIDSe Weight loss, 
dysphagia, ody-
nophagia, fatigue 
for 1 month, fe-
ver, pancytopenia
CVCa > 30 days No Vancomycin 8 days
Continued next page
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Discussion
Brevibacterium spp. are gram-positive, irregular, rod-
shaped, non-acid-fast bacteria which resemble coryne-
bacteria. At the present time, ten species are classified in 
this genus: B. linens, B. iodinum, B. epidermidis, B. casei, 
B. mcbrellneri, B. otitidis, B. avium, B. paucivorans, 
B. luteolum and B. sanguinis [4–7]. The main habitat of Brevi-
bacterium sp. are dairy products, where the bacteria contrib-
ute to the aroma and color. They are also found on human skin 
surfaces, genital hair and otorrhea [6, 8, 9]. 
Brevibacterium spp. had not been considered as hu-
man pathogens until about a decade ago. Since then, a few 
cases have been reported with Brevibacterium spp. caus-
ing disease in humans [1, 4, 10–18] (Table 1). Symptomatic 
bacteremia with Brevibacterium spp. are almost exclusively 
described in immunocompromised patients [1, 4, 10–12, 14, 
15], two of them infected with HIV type 1 [4, 11], the oth-
ers induced by treatment of malignant disease [10, 12, 14, 
15]. All but one had an indwelling CVC as an additional 
risk factor [1, 4, 10–14]. Only three patients with Brevi-
bacterium sp. bacteremia [13, 16] were not conventionally 
immunocompromised but suffered from severe disease. All 
of these three, seven of the eight immunocompromised pa-
tients with bacteremia and the two patients with peritonitis 
[17, 18] had indwelling foreign material (CVC [1, 4, 10–14], 
prosthetic mitral and aortic valve [16], or continuous am-
bulatory peritoneal dialysis catheter [17, 18]) as risk factors 
for infection.
The clinical presentation of Brevibacterium sp. in-
fection varied with the underlying disease (Table 1). All 
patients presented with elevated body temperature, some 
of the patients with chills; most patients had additional 
unspecific symptoms such as weakness, general discom-
fort, weight loss and reduced appetite. Exacerbation of 
symptoms related to underlying disease was also observed 
(gastrointestinal discomfort in CPAP patients, dyspnea 
and cough in our patient with pulmonary hypertension). 
Moderately elevated CRP-levels were reported in only 
three patients (our patient [12, 18]). Only the patient with 
lymphocytic leukemia presented with leukocytosis. Al-
though it is comprehensible that elevation of inflammatory 
markers (CRP, leukocytes) were only moderate or absent 
in this predominantly immunocompromised patient, Bre-
vibacterium spp. seem to only mildly activate the immune 
response in their hosts; the CRP in our immunocompe-
tent patient was only slightly elevated. The time from 
onset of symptoms to diagnosis and therapy varied between 
rapid onset with fever and chills, and lingering disease 
with unspecific symptoms for up to 2 months. Recurrence 
was reported in about a quarter of the patients (Table 1). 
Indwelling foreign material can be a risk factor of 
catheter-related bloodstream infections (CR-BSI). Beside 
common causative pathogens, a variety of unusual patho-
gens may also be encountered, particularly in immunocom-
pro-mised patients [19]. The observation of Brevibacterium
sp. in blood cultures of patients with corresponding clinical 
symptoms is new and adds this species to the list of unusual 
pathogens. Accordingly, apart from in vitro susceptibility 
tests [20], little is known about the preferable antibiotic 
therapy and its required duration in vivo. Vancomycin was 
the therapeutic agent most frequently reported for around 
8 days in septicemia and up to 6 weeks in endocarditis. 
Others used other glycopeptides (teicoplanin), penicil-
lin-derivates (piperacillin) or chinolones (ciprofloxacin, 
moxifloxacin) or combinations. The choice and duration 
of therapy will strongly depend on clinical symptoms, site 
of infection and underlying disease. 
We present this case report as patients suffering from 
infections caused by Brevibacterium sp. may present with 
sparse and often unrecognized symptoms, possibly related 
to the underlying disease. Underestimation of these unspe-
cific but relevant clinical symptoms and misinterpretation 
as apathogenic organisms may considerably delay diagno-
sis and treatment of this emerging, mainly opportunistic 
pathogen. Therefore, it is important to sensitize  physi-
cians and microbiologists to this environmental pathogenic 
Table 1 (continued)
Reference Type of 
Infection
Brevibacte-
rium species
Main 
underlying 
disease
Clinical 
symptoms
Indwelling 
foreign 
material
Symptom 
onset to 
treatment
Time to 
recurrence 
(days)
Treatment 
regimen(s)
Dass [16] Endocarditis Otitidis Prosthetic mi-
tral and aortic 
valve replace-
ment
Fever and chills 
for 4 days, mal-
aise, loss of ap-
petite, fatigue
Prosthetic 
valve
4 days No Vancomycin 
6 weeks  and 
gentamicin 
2 weeks
Our patient Septicemia Casei Continuous 
iv-iloprost in 
pulmonary 
hypertension
Fever, chills, 
fatigue, cough, 
dyspnea previous 
1–2 month, CRPb 
max 36 mg/dl
CVCa > 1 
months
No Vancomycin 
10 days followed 
by moxifloxacin 
21 days
a Central venous catheter; b C-reactive protein; c continuous ambulatory peritoneal dialysis; d polymorph nuclear neutrophils; e acquired 
immunodeficiency syndrome 
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microorganism possibly severely affecting profoundly ill 
patients.
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